

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)



(10) International Publication Number
WO 2023/064886 A1

(51) International Patent Classification:

A61K 9/19 (2006.01) A61K 47/26 (2006.01)
A61K 47/02 (2006.01) A61P 7/04 (2006.01)
A61K 47/18 (2006.01) A61K 47/10 (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2022/078097

(22) International Filing Date:

14 October 2022 (14.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/256,432 15 October 2021 (15.10.2021) US

(71) Applicant: BIOVERATIV THERAPEUTICS INC.

[US/US]; 225 Second Avenue, Waltham, Massachusetts
02451 (US).

(72) Inventors: CARLAGE, Tyler; c/o Bioverativ Therapeu-

tics Inc., 225 Second Avenue, Waltham, Massachusetts
02451 (US). MAULDIN, Randall; c/o Bioverativ Thera-
peutics Inc., 225 Second Avenue, Waltham, Massachusetts
02451 (US). MCCOY, Timothy R.; c/o Bioverativ Thera-
peutics Inc., 225 Second Avenue, Waltham, Massachusetts
02451 (US). TAZI, Loubna Mzaalak; c/o Bioverativ Ther-
apeutics Inc., 225 Second Avenue, Waltham, Massachusetts
02451 (US).

(74) Agent: VELEMA, James H. et al.; Lathrop GPM LLP, 28

State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: FORMULATIONS OF FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF

(57) Abstract: The present disclosure provides pharmaceutical compositions of a chimeric protein comprising a factor VIII (FVIII) polypeptide and a von Willebrand factor (VWF) polypeptide. Also disclosed are pharmaceutical kits and methods of using the disclosed pharmaceutical compositions to treat hemophilia A.

WO 2023/064886 A1